ArticleNPJ precision oncology2021

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.

Charlotte E J Downes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.